Advanced search
1 file | 416.36 KB Add to list

Nephrotoxicity of anticancer drugs: an underestimated problem?

Norbert Lameire (UGent) , VIBEKE KRUSE (UGent) and Sylvie Rottey (UGent)
(2011) ACTA CLINICA BELGICA. 66(5). p.337-345
Author
Organization
Abstract
Nephrotoxicity is an inherent adverse effect of certain anticancer drugs and may result in a variety of functional consequences that include any combination of glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function. The nephrotoxic potential of most anticancer agents dramatically increases in the presence of borderline or overt pre-existing chronic kidney disease and measurement of renal function is therefore of utmost importance in the cancer patient before any treatment is initiated. This review summarizes some clinical nephrotoxic side effects of a selection of the most frequently used anticancer drugs. The drugs discussed are cisplatin, methotrexate, ifosfamide, cituximab and panitumumab, mitocin C and gemcitabine and antiangiogenesis drugs.
Keywords
ACUTE KIDNEY INJURY, cancer, targeted agents, nephrotoxicity, chemotherapy, ACUTE-RENAL-FAILURE, IFOSFAMIDE-INDUCED NEPHROTOXICITY, CANCER-PATIENTS, THROMBOTIC MICROANGIOPATHY, SIGNALING PATHWAY, CISPLATIN NEPHROTOXICITY, CLINICAL-PRACTICE, CELL CARCINOMA, RISK-FACTORS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 416.36 KB

Citation

Please use this url to cite or link to this publication:

MLA
Lameire, Norbert, et al. “Nephrotoxicity of Anticancer Drugs: An Underestimated Problem?” ACTA CLINICA BELGICA, vol. 66, no. 5, 2011, pp. 337–45, doi:10.2143/ACB.66.5.2062585.
APA
Lameire, N., KRUSE, V., & Rottey, S. (2011). Nephrotoxicity of anticancer drugs: an underestimated problem? ACTA CLINICA BELGICA, 66(5), 337–345. https://doi.org/10.2143/ACB.66.5.2062585
Chicago author-date
Lameire, Norbert, VIBEKE KRUSE, and Sylvie Rottey. 2011. “Nephrotoxicity of Anticancer Drugs: An Underestimated Problem?” ACTA CLINICA BELGICA 66 (5): 337–45. https://doi.org/10.2143/ACB.66.5.2062585.
Chicago author-date (all authors)
Lameire, Norbert, VIBEKE KRUSE, and Sylvie Rottey. 2011. “Nephrotoxicity of Anticancer Drugs: An Underestimated Problem?” ACTA CLINICA BELGICA 66 (5): 337–345. doi:10.2143/ACB.66.5.2062585.
Vancouver
1.
Lameire N, KRUSE V, Rottey S. Nephrotoxicity of anticancer drugs: an underestimated problem? ACTA CLINICA BELGICA. 2011;66(5):337–45.
IEEE
[1]
N. Lameire, V. KRUSE, and S. Rottey, “Nephrotoxicity of anticancer drugs: an underestimated problem?,” ACTA CLINICA BELGICA, vol. 66, no. 5, pp. 337–345, 2011.
@article{1998680,
  abstract     = {{Nephrotoxicity is an inherent adverse effect of certain anticancer drugs and may result in a variety of functional consequences that include any combination of glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function.
The nephrotoxic potential of most anticancer agents dramatically increases in the presence of borderline or overt pre-existing chronic kidney disease and measurement of renal function is therefore of utmost importance in the cancer patient before any treatment is initiated.
This review summarizes some clinical nephrotoxic side effects of a selection of the most frequently used anticancer drugs. The drugs discussed are cisplatin, methotrexate, ifosfamide, cituximab and panitumumab, mitocin C and gemcitabine and antiangiogenesis drugs.}},
  author       = {{Lameire, Norbert and KRUSE, VIBEKE and Rottey, Sylvie}},
  issn         = {{0001-5512}},
  journal      = {{ACTA CLINICA BELGICA}},
  keywords     = {{ACUTE KIDNEY INJURY,cancer,targeted agents,nephrotoxicity,chemotherapy,ACUTE-RENAL-FAILURE,IFOSFAMIDE-INDUCED NEPHROTOXICITY,CANCER-PATIENTS,THROMBOTIC MICROANGIOPATHY,SIGNALING PATHWAY,CISPLATIN NEPHROTOXICITY,CLINICAL-PRACTICE,CELL CARCINOMA,RISK-FACTORS}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{337--345}},
  title        = {{Nephrotoxicity of anticancer drugs: an underestimated problem?}},
  url          = {{http://doi.org/10.2143/ACB.66.5.2062585}},
  volume       = {{66}},
  year         = {{2011}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: